Incyte Corporation (INCY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $127.00 (-0.49%), Market cap $19.50B, P/E ratio 13.79, 52-week low–high $63.31 ~ $110.57.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 f
Financial statements, price targets, institutional (13F) holdings and related news for Incyte Corporation are updated in real time on BlackAll Trade.
Incyte Corporation trades at $127.00 (-0.49%). Real-time quotes and charts are available on BlackAll Trade.
Incyte Corporation has a market cap of about $19.50B. Its P/E ratio is 13.79.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI